Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CETP | P11597 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18683671 | 1.00 | GAA (0.48) | GAALGALS3LGALS8LGALS4L3MBTL1 | |
| SCHEMBL17547740 | 1.00 | GAA (0.48) | GAALGALS3LGALS8LGALS4L3MBTL1 | |
| SCHEMBL26167579 | 1.00 | GAA (0.48) | GAALGALS3LGALS8LGALS4L3MBTL1 | |
| SCHEMBL17524277 | 1.00 | GAA (0.48) | GAALGALS3LGALS8LGALS4L3MBTL1 | |
| SCHEMBL26442857 | 1.00 | GAA (0.48) | GAALGALS3LGALS8LGALS4L3MBTL1 | |
| SCHEMBL17297156 | 1.00 | GAA (0.48) | GAALGALS3LGALS8LGALS4L3MBTL1 | |
| SCHEMBL14925477 | 1.00 | GAA (0.48) | GAALGALS3LGALS8LGALS4L3MBTL1 | |
| SCHEMBL13553151 | 0.92 | GAA (0.54) | GAALGALS3LGALS8LGALS4L3MBTL1 | |
| SCHEMBL15501194 | 0.92 | GAA (0.54) | GAALGALS3LGALS8LGALS4L3MBTL1 | |
| SCHEMBL20267325 | 0.92 | GAA (0.54) | GAALGALS3LGALS8LGALS4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180066255-A1 | Compositions and Methods for Inhibition of Expression of Protein C (PROC) Genes | BANK OF AMERICA, N.A. | 2018-03-08 | — | — | US | disclosed |
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
| US-9566340-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160101189-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2016-04-14 | — | — | US | disclosed |
| US-9198972-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20130053334-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053334-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | DNMT1, FANCI, PCNA | GAA 1704/4885LGALS3 1544/4885LGALS8 2021/4885 |
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | GAA 1585/4885LGALS3 1473/4885LGALS8 2006/4885 |
| US-20160101189-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | GAA 1585/4885LGALS3 1473/4885LGALS8 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.